Highlight
This comprehensive individual participant data meta-analysis assessed the effectiveness and safety of mineralocorticoid receptor antagonists (MRAs) in Black versus non-Black patients with heart failure (HF). No significant racial differences were found in treatment outcomes or adverse event profiles across HF phenotypes. Despite younger age, Black patients experienced higher rates of HF hospitalization and mortality, underscoring the critical need for equitable therapeutic application.
